Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2024 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Conference Call and Webcast Scheduled for November 7, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a...
October 29, 2024 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

RMAT Designation Follows Positive Proof-of-Concept Data from the ALLO-316 TRAVERSE Trial in Adult Patients with Advanced or Metastatic CD70 Positive Renal Cell Carcinoma (RCC) Who Received Prior...
September 30, 2024 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
September 26, 2024 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence

The CD19/CD70 Dual CAR is Specifically Designed to Address Both the B-cell and T-cell Dysfunction Implicated in Autoimmune DiseasesALLO-329, is an Investigational Product Built on a New Gene Editing...
August 08, 2024 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
August 07, 2024 16:02 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Cemacabtagene Ansegedleucel (Cema-Cel): 1L Consolidation in Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Initiated in June 2024Patient Screening for Minimal Residual Disease (MRD) and...
July 31, 2024 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Conference Call and Webcast Scheduled for August 7, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a...
July 01, 2024 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton...
June 20, 2024 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

ALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure RatesFirst Prospective Trial to Incorporate the Foresight Diagnostics’s...
May 23, 2024 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...